Lung Cancer Trial, Recruiting NCT06052098 Sponsor: Hangzhou Broncus Medical Co., Ltd. Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT06052098
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged over 18 years
  • People who have been diagnosed with primary peripheral lung cancer (a specific type and location of lung tumour) confirmed by a pathology test, and whose cancer has been staged as Stage IA (T1N0M0) before any treatment
  • People whose tumour has been assessed by doctors as suitable for a type of ablation (a procedure that destroys tumour tissue) guided by CT scan and bronchoscopy (a camera inserted into the airways)
  • People who have been assessed as not suitable for surgery, or who have chosen not to have surgery, and who agree to have ablation as their first treatment and have signed a consent form

Who may not be able to join:

  • People with a very low platelet count or serious blood clotting problems that cannot be corrected quickly
  • People with severe lung scarring (pulmonary fibrosis) or high blood pressure in the lungs (pulmonary hypertension)
  • People with an active infection near the tumour, skin infection at the planned procedure site that is not well controlled, a body-wide infection, or a high fever above 38.5°C
  • People with serious problems affecting the liver, kidneys, heart, lungs, or brain, or severe anaemia, dehydration, or nutritional problems that cannot be corrected or improved in a short period of time
  • People with a build-up of fluid around the lung (pleural effusion) that is not well controlled
  • People who have been taking blood-thinning or anti-clotting medications (with some exceptions such as dabigatran and rivaroxaban) and have stopped taking them for fewer than 5–7 days before the procedure
  • People with a functional status score greater than 2 on the ECOG scale, meaning people whose illness significantly limits their daily activity (confirm with trial site)
  • People who have another cancer that has spread widely through the body, with an expected survival of less than 6 months
  • People with episodic (recurring) psychiatric illness
  • People who have an implanted electronic device such as a pacemaker or defibrillator
  • People who are pregnant, or who plan to become pregnant during the study period
  • People who are currently participating in, or have participated in, another clinical trial within the past 30 days
  • People whom the trial investigators consider unsuitable for the study for other reasons

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jiayuan Sun, MD, PhD, Shanghai Chest Hospital

Phone: 86-021-22200000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Hangzhou Broncus Medical Co., Ltd.
Registry
ClinicalTrials.gov
Start date
11 October 2023
Est. completion
1 April 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Complete ablation rate at 6 months after ablation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov